Morphological Features of Metastatic Gastrointestinal Stromal Tumors after Gleevec Treatment - Two Cases Report -
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
We report two patients with metastatic gastrointestinal stromal tumors (GISTs) with a focus on the morphological features related to Gleevec treatment. In case 1, a 50-year-old woman presented with a 1.8 ㎝ metastatic GIST in the liver after resection of a gastric GIST. Majority of the metastatic tumor showed fibrosis and hyalinization after 8 weeks of Gleevec treatment. CD117-positive cells were present in approximately 1% of the overall tumor. In case 2, a 2 ㎝ and 14 ㎝ metastatic liver masses were found in a 54-year-old man who had a rectal GIST. After 4 weeks of Gleevec treatment, metastatic tumors showed a decrease in size on CT scan. The metastatic tumors showed a decrease in number of tumor cells. The hemorrhage, cystic changes, necrosis, and fibrosis made up approximately 90% of the tumor. The morphological features related to Gleevec treatment are important for correct diagnosis and evaluation of tumor response and prognosis.
Abstract
We report two patients with metastatic gastrointestinal stromal tumors (GISTs) with a focus on the morphological features related to Gleevec treatment. In case 1, a 50-year-old woman presented with a 1.8 ㎝ metastatic GIST in the liver after resection of a gastric GIST. Majority of the metastatic tumor showed fibrosis and hyalinization after 8 weeks of Gleevec treatment. CD117-positive cells were present in approximately 1% of the overall tumor. In case 2, a 2 ㎝ and 14 ㎝ metastatic liver masses were found in a 54-year-old man who had a rectal GIST. After 4 weeks of Gleevec treatment, metastatic tumors showed a decrease in size on CT scan. The metastatic tumors showed a decrease in number of tumor cells. The hemorrhage, cystic changes, necrosis, and fibrosis made up approximately 90% of the tumor. The morphological features related to Gleevec treatment are important for correct diagnosis and evaluation of tumor response and prognosis.
참고문헌 (17)
- Fletcher CD, "Diagnosis of gastrointestinal stromal tumors: a consensus approach", Hum Pathol, 33, pp.459~465 (2002)
- Joensuu H, "Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor", N Engl J Med, 344, pp.1052~1056 (2001)
- Chen MY, "Cystic changes in hepatic metastases from gastrointestinal stromal tumors (GISTs) treated with Gleevec (imatinib mesylate)", AJR Am J Roentgenol, 179, pp.1059~1062 (2002)
- Bechtold RE, "Cystic changes in hepatic and peritoneal metastases from gastrointestinal stromal tumors treated with Gleevec", Abdom Imaging, 28, pp.808~814 (2003)
- Colecchia M, "Images in pathology. Morphologic features of response to Gleevec (Imatinib) treatment of GIST", Int J Surg Pathol, 11, pp.119~ (2003)
- Ho_genauer C, "Complete remission of a metastatic gastrointestinal stromal tumour with the tyrosine kinase inhibitor imatinib (STI 571):effect of low dosage in an advanced tumour with exon 11 mutation", Eur J Gastroenterol Hepatol, 15, pp.323~327 (2003)
- Pauwels P, "Changing phenotype of gastrointestinal stromal tumours under imatinib mesylate treatment: a potential diagnostic pitfall", Histopathology, 47, pp.41~47 (2005)
- Suzuki S, "Pathologic complete response confirmed by surgical resection for liver metastases of gastrointestinal stromal tumor after treatment with imatinib mesylate", World J Gastroenterol, 14, pp.3763~3767 (2008)
- Heinrich MC, "Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations", Hum Pathol, 33, pp.484~495 (2002)
- Judson I, "Advances in the treatment of gastrointestinal stromal tumours", Ann Oncol, 18(10), pp.x20~x24 (2007)
- Dematteo RP, "Clinical management of gastrointestinal stromal tumors: before and after STI-571", Hum Pathol, 33, pp.466~477 (2002)
- Torihashi S, "Blockade of kit signaling induces transdifferentiation of interstitial cells of Cajal to a smooth muscle phenotype", Gastroenterology, 117, pp.140~148 (1999)
- Liegl B, "Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy. A novel form of tumor progression", Am J Surg Pathol, 33, pp.218~226 (2008)
- Heinrich MC, "Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor", J Clin Oncol, 21, pp.4342~4349 (2003)
- Antonescu CR, "Targeted therapy of cancer: new roles for pathologists in identifying GISTs and other sarcomas", Mod Pathol, 21, pp.S31~S36 (2008)
- Miettinen M, "Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis", Arch Pathol Lab Med, 130, pp.1466~1478 (2006)
- Kirsch R, "Gastrointestinal stromal tumors: diagnostic challenges and practical approach to differential diagnosis", Adv Anat Pathol, 14, pp.261~285 (2007)